Background
Methods
Patients
Diagnosis and definitions
Treatment
Statistics
Results
Patient characteristics
Number of patients | 1317 |
Age (years, mean ± standard deviation [SD]) | 64 ± 13 |
Male/female (%) | 78/22 |
Etiology of cirrhosis (%) | |
Hepatitis B | 721 (55) |
Hepatitis C | 349 (27) |
Alcoholism | 308 (23) |
Serum biochemistry (mean ± SD) | |
Albumin (g/dL) | 3.6 ± 0.6 |
Bilirubin (mg/dL) | 1.4 ± 2.2 |
Creatinine (mg/dL) | 1.2 ± 1.3 |
Estimated glomerular filtration rate (ml/min/1.73m2) | 78 ± 36 |
International normalized ratio of prothrombin time | 1.1 ± 0.1 |
Child-Turcotte-Pugh class A/B (%) | 69/31 |
Number and size of tumor (%) | |
Single/multiple | 59/41 |
≤ 5 cm/ > 5 cm | 36/64 |
Total tumor volume (cm3, mean ± SD [median]) | 566 ± 861 (193) |
Vascular invasion (%) | 591 (45) |
Metastasis/lymph node | 198 (15) |
α-fetoprotein (ng/mL, mean ± SD [median]) | 34,136 ± 177,031 (118) |
Tumor burden 0/1/2/3 (%) | 4.5/17.2/28.3/50 |
Ascites (%) | 398 (30) |
Performance status 0/1/2 (%) | 24/53/23 |
Diabetes mellitus (%) | 358 (27) |
Treatment modality (%) | |
Resection | 282 (21) |
Transplantation | 4 (0.3) |
Ablation | 149 (11) |
Transarterial chemo-embolization | 437 (33) |
Targeted therapy | 107 (8) |
Best supportive care | 338 (26) |
Distribution of nomogram points and primary anti-cancer treatments
Characteristics of patients divided by nomogram points
Nomogram points | 3–4.2 (n = 241) | 6.7–10 (n = 545) | 11.9–13 (n = 301) | 15.2–18 (n = 230) | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
SR/Ablation/ TACE/ Transplant (n = 226) | Targeted/ Supportive (n = 15) | P | SR/Ablation/ TACE/ Transplant (n = 448) | Targeted/ Supportive (n = 97) | P | SR/Ablation/ TACE/ Transplant (n = 152) | Targeted/ Supportive (n = 149) | P | SR/Ablation/ TACE/ Transplant (n = 46) | Targeted/ Supportive (n = 184) | p | |
Age | 67 ± 12 | 72 ± 10 | 0.173 | 65 ± 13 | 64 ± 15 | 0.878 | 64 ± 14 | 64 ± 15 | 0.296 | 59 ± 13 | 62 ± 13 | 0.113 |
Male (%) | 166 (73) | 14 (93) | 0.124 | 340 (76) | 71 (73) | 0.576 | 117 (77) | 125 (84) | 0.131 | 36 (78) | 162 (88) | 0.086 |
HBV (%) | 110 (49) | 4 (27) | 0.115 | 238 (53) | 55 (57) | 0.522 | 85 (56) | 87 (58) | 0.665 | 30 (65) | 112 (61) | 0.587 |
HCV (%) | 81 (36) | 7 (47) | 0.399 | 130 (29) | 24 (25) | 0.397 | 27 (18) | 33 (22) | 0.341 | 10 (22) | 37 (20) | 0.806 |
Alcoholism (%) | 47 (21) | 2 (13) | 0.742 | 99 (22) | 14 (14) | 0.091 | 41 (27) | 36 (24) | 0.576 | 12 (26) | 57 (31) | 0.517 |
CTP class A (%) | 225 (100) | 14 (93) | 0.121 | 371 (83) | 83 (86) | 0.51 | 99 (65) | 117 (79) | 0.01 | 0 | 0 | N/A |
Ascites (%) | 21 (9) | 2 (13) | 0.642 | 83 (19) | 20 (21) | 0.633 | 61 (40) | 48 (32) | 0.153 | 30 (65) | 133 (72) | 0.346 |
eGFR > 60 (ml/min/1.73m2) | 173 (77) | 5 (33) | 0.001 | 338 (75) | 71 (73) | 0.642 | 114 (75) | 111 (75) | 0.92 | 37 (80) | 144 (78) | 0.747 |
Tumor > 5 cm | 26 (12) | 6 (40) | 0.007 | 280 (63) | 75 (77) | 0.006 | 121 (80) | 135 (91) | 0.008 | 34 (74) | 160 (87) | 0.029 |
Single tumor (%) | 167 (74) | 8 (53) | 0.084 | 278 (62) | 53 (55) | 0.175 | 73 (48) | 81 (54) | 0.272 | 23 (50) | 89 (48) | 0.843 |
Tumor burden 0/1/2/3 | 16/69/14/0 | 13/40/47/0 | 0.008 | 4/12/50/34 | 3/8/27/62 | <.001 | 0/0/35/65 | 0/0/21/79 | 0.01 | 0/0/0/100 | 0/0/0/100 | N/A |
Performance status 0/1/2 (%) | 17/64/19 | 47/33/20 | 0.014 | 35/47/18 | 66/21/13 | <.001 | 0/68/32 | 0/69/31 | 0.799 | 30/46/24 | 20/48/32 | 0.239 |
Vascular invasion (%) | 0 | 0 | N/A | 136 (30) | 57 (59) | <.001 | 84 (55) | 107 (72) | 0.003 | 37 (80) | 170 (92) | 0.016 |
Metastasis/lymph node (%) | 0 | 0 | N/A | 27 (6) | 15 (15) | 0.002 | 30 (20) | 47 (32) | 0.019 | 14 (30) | 65 (35) | 0.532 |
AFP > 400 ng/mL | 33 (15) | 3 (20) | 0.475 | 137 (31) | 50 (52) | <.001 | 68 (45) | 92 (62) | 0.003 | 22 (48) | 115 (63) | 0.07 |
Diabetes mellitus (%) | 76 (34) | 6 (40) | 0.614 | 112 (25) | 23 (24) | 0.79 | 47 (31) | 46 (31) | 0.993 | 10 (22) | 38 (21) | 0.871 |
Comparison of survival between patients receiving different treatments stratified by nomogram points
Characteristics of patients in the propensity model divided by nomogram points
Nomogram points/Absolute difference in propensity score of matched pairs | 3–4.2 (n = 30)/< 0.0001 | 6.7–10 (n = 174)/0.0007 | 11.9–13 (n = 224)/0.0007 | 15.2–18 (n = 90)/< 0.0001 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
SR/Ablation/ TACE/ Transplant (n = 15) | Targeted/ Supportive (n = 15) | P/Stddiff | SR/Ablation/ TACE/ Transplant (n = 87) | Targeted/ Supportive (n = 87) | P/Stddiff | SR/Ablation/ TACE/ Transplant (n = 112) | Targeted/ Supportive (n = 112) | P/Stddiff | SR/Ablation/ TACE/ Transplant (n = 45) | Targeted/ Supportive (n = 45) | P/Stddiff | |
Age | 75 ± 13 | 72 ± 10 | 0.92/0.14 | 63 ± 14 | 65 ± 14 | 0.21/0.18 | 63 ± 15 | 64 ± 14 | 0.06/0.3 | 59 ± 14 | 61 ± 13 | 0.094/0.16 |
Male (%) | 13 (87) | 14 (93) | 1/0.14 | 65 (75) | 66 (76) | 0.86/0.18 | 84 (75) | 93 (83) | 0.14/0.3 | 35 (78) | 39 (87) | 0.27/0.61 |
HBV (%) | 6 (40) | 4 (27) | 0.7/0.29 | 47 (54) | 48 (55) | 0.88/0.02 | 64 (57) | 65 (58) | 0.89/0.02 | 30 (67) | 21 (47) | 0.056/0.41 |
HCV (%) | 5 (33) | 7 (47) | 0.46/0.27 | 27 (31) | 22 (25) | 0.4/0.13 | 19 (17) | 23 (21) | 0.49/0.09 | 9 (20) | 13 (29) | 0.327/0.21 |
Alcoholism (%) | 2 (13) | 2 (13) | 1/0 | 10 (11) | 13 (15) | 0.5/0.1 | 28 (25) | 32 (29) | 0.55/0.08 | 11 (24) | 14 (31) | 0.48/0.15 |
CTP class A (%) | 15 (100) | 14 (93) | 1/0.38 | 72 (83) | 74 (85) | 0.68/0.06 | 85 (76) | 80 (81) | 0.45/0.1 | 0 | 0 | N/A |
Ascites (%) | 2 (13) | 2 (13) | 1/0 | 15 (17) | 18 (21) | 0.56/0.09 | 37 (33) | 41 (37) | 0.58/0.08 | 29 (64) | 34 (76) | 0.25/0.24 |
eGFR > 60 (ml/min/1.73m2) | 5 (33) | 5 (33) | 1/0 | 62 (71) | 65 (75) | 0.61/0.08 | 83 (74) | 79 (71) | 0.55/0.08 | 37 (82) | 33 (73) | 0.311/0.22 |
Tumor > 5 cm | 6 (40) | 6 (40) | 1/0 | 66 (76) | 65 (75) | 0.86/0.03 | 96 (86) | 99 (88) | 0.55/0.08 | 34 (76) | 34 (76) | 1/0 |
Single tumor (%) | 11 (73) | 8 (53) | 0.26/0.42 | 56 (64) | 47 (54) | 0.17/0.21 | 57 (51) | 50 (45) | 0.35/0.13 | 23 (51) | 21 (47) | 0.673/0.09 |
Tumor burden 0/1/2/3 | 7/53/40/0 | 13/40/47/0 | 0.67/0.31 | 2/13/28/57 | 3/9/29/59 | 0.87/0.13 | 0/0/24/76 | 0/0/29/71 | 0.45/0.13 | 0/0/0/100 | 0/0/0/100 | N/A |
Performance status 0/1/2 (%) | 40/40/20 | 47/33/20 | 0.9/0.15 | 60/22/18 | 62/23/15 | 0.83/0.09 | 0/71/29 | 0/71/29 | 1/0 | 29/47/24 | 20/40/40 | 0.266/0.35 |
Vascular invasion (%) | 0 | 0 | N/A | 47 (54) | 49 (56) | 0.76/0.05 | 72 (64) | 71 (63) | 0.89/0.02 | 37 (82) | 37 (82) | 1/0 |
Metastasis/lymph node (%) | 0 | 0 | N/A | 8 (9) | 9 (10) | 0.8/0.04 | 26 (23) | 31 (28) | 0.44/0.1 | 13 (29) | 21 (47) | 0.08/0.37 |
AFP > 400 ng/mL | 3 (20) | 3 (20) | 1/0 | 44 (51) | 42 (48) | 0.76/0.05 | 65 (58) | 61 (54) | 0.59/0.07 | 22 (49) | 28 (62) | 0.203/0.27 |
Diabetes mellitus (%) | 7 (47) | 6 (40) | 0.71/0.13 | 18 (21) | 20 (23) | 0.71/0.06 | 32 (29) | 39 (35) | 0.31/0.13 | 9 (20) | 9 (20) | 1/0 |